Annovis Bio Files 8-K
Ticker: ANVS · Form: 8-K · Filed: May 21, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Annovis Bio filed a standard 8-K, check exhibits for details.
AI Summary
Annovis Bio, Inc. filed an 8-K on May 21, 2024, reporting on its financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for a Form 8-K.
Why It Matters
This filing indicates Annovis Bio is meeting its regulatory reporting obligations. Investors should review the exhibits for any specific disclosures.
Risk Assessment
Risk Level: low — This is a routine regulatory filing with no new material information disclosed.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- May 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 101 Lindenwood Drive, Suite 225 (address) — Principal Executive Offices
- Malvern, PA 19355 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of May 21, 2024.
What is the exact name of the registrant?
The exact name of the registrant is Annovis Bio, Inc.
In which state was Annovis Bio, Inc. incorporated?
Annovis Bio, Inc. was incorporated in Delaware.
What is the address of Annovis Bio, Inc.'s principal executive offices?
The address of Annovis Bio, Inc.'s principal executive offices is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What is the Commission File Number for Annovis Bio, Inc.?
The Commission File Number for Annovis Bio, Inc. is 001-39202.
Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-05-21 16:05:24
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2415055d1_8k.htm (8-K) — 25KB
- tm2415055d1_ex99-1.htm (EX-99.1) — 10KB
- 0001104659-24-063829.txt ( ) — 210KB
- anvs-20240521.xsd (EX-101.SCH) — 3KB
- anvs-20240521_lab.xml (EX-101.LAB) — 33KB
- anvs-20240521_pre.xml (EX-101.PRE) — 22KB
- tm2415055d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On May 21, 2024, Annovis Bio, Inc. (the "Company") issued a press release dated May 21, 2024 which is being furnished as Exhibit 99.1 hereto. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated May 21, 2024 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: May 21, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer